UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 000-01227 Chicago Rivet & Machine Co. (Exact name of registrant as specified in its charter) | Illinois | 36-0904920 | | --- | --- | | (State or other jurisdiction | (I.R.S. Employer | ...

Core Viewpoint - The article discusses the investment potential of UAN shares, highlighting the author's positive outlook based on personal analysis and market conditions [1]. Group 1: Company Analysis - UAN has shown strong performance metrics that suggest a favorable investment opportunity [1]. - The author emphasizes the importance of understanding market dynamics and company fundamentals when considering UAN shares [1]. Group 2: Industry Insights - The broader industry context is essential for evaluating UAN's position and potential growth [1]. - Market trends indicate a positive trajectory for companies within the same sector, which may benefit UAN [1].

Core Viewpoint - CVR Partners, LP has filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2025, with the Securities and Exchange Commission, which is accessible on its website [1] Company Information - CVR Partners, LP is a manufacturer of ammonia and urea ammonium nitrate (UAN) solution fertilizer products [1] - Unitholders can request a printed copy of the Annual Report free of charge [1]

Core Insights - NewcelX has published a peer-reviewed scientific review on Mazindol Immediate-Release/Sustained-Release (IR/SR), enhancing its strategic positioning and supporting discussions related to its Contingent Value Right (CVR) framework [1] - The publication provides independent validation of Mazindol ER's clinical and mechanistic profile, which is expected to strengthen buyer confidence and facilitate licensing and acquisition discussions [1] - NewcelX is currently in advanced discussions with multiple parties regarding potential licensing and acquisition transactions for Mazindol ER, aiming to optimize transaction terms and maximize CVR value realization [1] Company Developments - The peer-reviewed publication marks a significant milestone, reflecting over 20 years of research dedicated to Mazindol ER, which targets large markets such as narcolepsy, ADHD, and substance use disorders [1] - NewcelX's management emphasizes the importance of converting the scientific strength of Mazindol ER into strategic and financial outcomes, enhancing its negotiating position in ongoing discussions [1] - The company is focused on executing a strategic transaction that crystallizes the intrinsic value of Mazindol ER, delivering measurable returns to CVR holders and shareholders [1] Industry Context - NewcelX operates in the biopharmaceutical sector, specifically developing stem-cell-derived therapies for Type 1 Diabetes and innovative treatments for central nervous system disorders [1] - The publication in a leading scientific journal is expected to enhance the visibility and long-term commercial potential of NewcelX's CNS pipeline [1] - The company utilizes a validated human pluripotent stem cell platform for its lead program, IsletRx, aimed at addressing critical unmet medical needs in Type 1 Diabetes [1]

Core Viewpoint - CVR Energy, Inc. announced the pricing of a private placement of $600 million in 7.500% senior unsecured notes due 2031 and $400 million in 7.875% senior unsecured notes due 2034, indicating a strategic move to raise capital through debt issuance [1] Group 1: Financial Details - The offering consists of $600 million in aggregate principal amount of 7.500% senior unsecured notes due 2031 [1] - Additionally, the offering includes $400 million in aggregate principal amount of 7.875% senior unsecured notes due 2034 [1] - The notes are being issued under Rule 144A and Regulation S of the Securities Act of 1933, as amended [1]

Core Viewpoint - CVR Energy, Inc. plans to offer $1 billion in senior unsecured notes due 2031 and 2034, subject to market conditions [1] Group 1: Offering Details - The offering will be conducted in a private placement under Rule 144A and Regulation S of the Securities Act of 1933 [1] - The notes include $1 billion in aggregate principal amount of senior unsecured notes due 2031 and senior unsecured notes due 2034 [1]

Core Viewpoint - CVR Partners, LP has announced preliminary capital spending estimates for 2026, ranging from $60 million to $75 million, indicating a focus on both maintenance and growth capital projects [1] Capital Expenditures Summary - Estimated maintenance capital expenditures for 2026 are projected to be between $35 million and $45 million, highlighting the company's commitment to maintaining operational efficiency [1] - Growth capital expenditures are expected to be in the range of $25 million to $30 million, reflecting the company's strategy to enhance margins and address bottlenecks in operations [1] - The total capital expenditures for 2026 are thus estimated to be between $60 million and $75 million, showcasing a balanced approach towards sustaining current operations while pursuing growth opportunities [1]

Core Insights - TuHURA Biosciences, Inc. has achieved a milestone in its clinical trial for REM-001, demonstrating safety and signs of clinical efficacy in ten metastatic cutaneous breast cancer patients after eight weeks of follow-up [1][2] Group 1: Company Overview - TuHURA Biosciences, Inc. is a Phase 3 immuno-oncology company focused on developing novel therapeutics to address resistance to cancer immunotherapy, a significant challenge in cancer treatment [3] - The company's lead product, IFx-2.0, aims to overcome primary resistance to checkpoint inhibitors and is currently in a Phase 3 trial as an adjunctive therapy to Keytruda® for advanced or metastatic Merkel Cell Carcinoma [4] Group 2: Recent Developments - Following the successful completion of the REM-001 trial, TuHURA will release an aggregate of 1,539,958 shares of common stock to legacy Kintara Therapeutics stockholders as per the Contingent Value Rights Agreement [2] - TuHURA has also acquired TBS-2025 through its merger with Kineta Inc., which is moving into Phase 2 development for mutNPM1 r/r AML [5]

Core Points - Gorilla Technology Group Inc. announced that holders of Class A contingent value rights (CVRs) will receive a distribution of ordinary shares, subject to the terms outlined in the Contingent Value Rights Agreement [1] - On November 18, 2025, 587,747 Earnout Shares were forfeited by Company Shareholders, which translates to 0.130382275 Ordinary Shares per Qualifying CVR Holder [2] - To become a Qualifying CVR Holder, a holder must submit a Valid Notice containing specific information; otherwise, the notice will be deemed invalid [3][4] Company Overview - Gorilla Technology Group Inc. is headquartered in London, UK, and operates as a global solution provider in Security Intelligence, Network Intelligence, Business Intelligence, and IoT technology [5] - The company offers a variety of solutions across sectors such as Government & Public Services, Manufacturing, Telecom, Retail, Transportation & Logistics, Healthcare, and Education, utilizing AI and Deep Learning Technologies [5] - Gorilla focuses on enhancing urban operations, security, and resilience through AI-driven products, including intelligent video surveillance and advanced cybersecurity technologies [6]

Core Insights - Investors in CVR Energy, Inc. (CVI) should monitor stock movements due to high implied volatility in the options market, particularly the Dec 19, 2025 $10 Put option [1] Company Overview - CVR Energy is currently rated as Zacks Rank 4 (Sell) in the Oil and Gas - Refining and Marketing industry, which is in the top 20% of the Zacks Industry Rank [3] - Over the past 30 days, no analysts have increased their earnings estimates for the current quarter, while one analyst has revised the estimate downward, leading to a consensus estimate change from earnings of 8 cents per share to a loss of 13 cents [3] Market Sentiment - The high implied volatility suggests that options traders are anticipating significant price movement for CVR Energy shares, indicating potential trading opportunities [4] - Seasoned options traders often seek high implied volatility options to sell premium, aiming for the underlying stock to not move as much as expected at expiration [4]